Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ESLAW
- Price
- 0.05
- Stock movement down
- -0.01 (-13.25%)
- Company name
- Estrella Immunopharma Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- 11.73M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
DIVIDENDS
ESLAW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -0.36 |
| FCF per share (TTM) | -0.07 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -13.50M |
| Net income (TTM) | -13.50M |
| EPS (TTM) | -0.36 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.63M |
| Net receivables | 396.90K |
| Total current assets | 2.02M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 3.52M |
| Accounts payable | 5.63K |
| Short/Current long term debt | 4.00K |
| Total current liabilities | 13.36M |
| Total liabilities | 13.36M |
| Shareholder's equity | -9.84M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.50M |
| Capital expenditures (TTM) | 4.00 |
| Free cash flow (TTM) | -2.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -383.16% |
| Return on Invested Capital | 137.25% |
| Cash Return on Invested Capital | 25.46% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.05 |
| Daily high | 0.05 |
| Daily low | 0.05 |
| Daily Volume | 1K |
| All-time high | 0.56 |
| 1y analyst estimate | - |
| Beta | -0.09 |
| EPS (TTM) | -0.36 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ESLAW | S&P500 | |
| Current price drop from All-time high | -90.92% | -2.53% |
| Highest price drop | -94.18% | -19.00% |
| Date of highest drop | 29 Jul 2025 | 8 Apr 2025 |
| Avg drop from high | -86.93% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 147 days | 89 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner